CBUS
Cibus, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.31
−0.76%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.31
From 52W high−67.65%
Volume36771.00
Market cap$100.12M
P/E (TTM)—
P/S (TTM)23.0x
Div yield—
Key dataOct 19, 2026
Open
$1.31
From 52W high
−67.65%
Volume
36771.00
Market cap
$100.12M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.0x
P/E (TTM)
—
RSI (14)
32.6
MomentumView details →
1D Return
−0.76%
YTD Return
−25.86%
SummaryUpdated Jun 1, 2026
Cibus, Inc. (NASDAQ:CBUS) is a San Diego-based agricultural biotechnology company founded in 2001 that develops gene-edited plant traits for licensing to seed companies. The company went public in July 2017 and has evolved from a research-focused organization into a commercial gene editing platform. Cibus specializes in developing productivity traits that help farmers achieve higher yields while reducing chemical inputs, as well as sustainable ingredients that can replace fossil fuel-based components in various products.
Similar companies
Latest newsMore news →
Cibus and Crystal Crop Protection announced a collaboration to improve mustard crop varieties in India using Cibus' gene-editing platform and Crystal Crop's mustard germplasm and distribution reach.21d agoCibus, Inc. announced its financial results for the quarter ended June 30, 2026, reporting a 19% sequential and 31% year-over-year decline in quarterly net cash usage.67d ago